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Abstract b-Amyloid (Ab) peptides may cause malfunc-
tion and death of neurons in Alzheimer’s disease. We
investigated the effect of Ab on key transporters of amino
acid neurotransmission in cells cultured from rat cerebral
cortex. The cultures were treated with Ab(25-35) at 3 and
10 lM for 12 and 24 h followed by quantitative analysis of
immunoﬂuorescence intensity. In mixed neuronal–glial cell
cultures (from P1 rats), Ab reduced the concentration of
system A glutamine transporter 1 (SAT1), by up to 50%
expressed relative to the neuronal marker microtubule-
associated protein 2 (MAP2) in the same cell. No signiﬁ-
cant effects were detected on vesicular glutamate
transporters VGLUT1 or VGLUT2 in neurons, or on glial
system N glutamine transporter 1 (SN1). In neuronal cell
cultures (from E18 rats), Ab(25-35) did not reduce SAT1
immunoreactivity, suggesting that the observed effect
depends on the presence of astroglia. The results indicate
that Ab may impair neuronal function and transmitter
synthesis, and perhaps reduce excitotoxicity, through a
reduction in neuronal glutamine uptake.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder,
leading to progressive loss of memory, impaired cognition
and debilitation. It affects about 2% of the population in
industrialized countries, the risk of having the disease
increasing rapidly with age beyond 70, hence the preva-
lence of AD will increase several fold in the coming
decades [1, 2]. AD is characterized by extracellular
deposits of b-amyloid (Ab), associated with dystrophic
neuronal processes, degenerating and apoptotic neurons
showing neuroﬁbrillary tangles (i.e. aggregates of hyper-
phosphorylated tau protein ﬁlaments).
The neurotoxic effects of Ab and some of its fragments
have been demonstrated in in vitro primary cultures from
human and rat cortical neurons, in hippocampal slice cul-
tures and following in vivo injection into various areas of
the rat and monkey brain [3]. Ab peptides cause neuronal
cell death and also increase the vulnerability of neurons to
excitotoxicity [4]. Ab(25-35) has been frequently used in
investigations of Ab properties as a less expensive and more
easily handled substitute for the native full-length peptide,
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DOI 10.1007/s11064-007-9527-2Ab(1-42), the latter being implicated in the pathogenesis of
AD. Implicit in these experiments is the assumption that the
mechanism of action of Ab(25-35) is similar to that of
Ab(1-42). Indeed, Ab(25-35) mimics the toxicological and
aggregational properties of the full-length peptide, though
these characteristics are increased; i.e., the shorter peptide is
more toxic to cultured neurons, exhibits toxicity earlier,
causes more membrane protein oxidation, and aggregates
faster than the native Ab(1-42) [5].
The amino acids glutamine and glutamate are essential for
brain metabolism and function. Glutamate is the major
excitatory transmitter of the brain [6], particularly in the
cerebral cortex and hippocampus, and therefore has important
roles in cognition, learning and memory. After synaptic
release, it is taken up mainly into astroglia by glutamate
transporters [7]. Perturbed glutamate uptake may cause
excitotoxicity and is implicated in the pathogenesis of AD [7].
Once accumulated into astrocytes, glutamate is converted to
the non-excitatory amino acid glutamine by the glial enzyme
glutamine synthetase. Glutamine is then returned to neurons
via glutamine transporters of system N (SNs) and system A
(SATs) and used as a source for the synthesis of glutamate
throughitsconversionbyphosphate-activatedglutaminase[8,
9]. Glutamate is packaged for exocytosis by vesicular gluta-
mate transporters (VGLUTs) [10, 11], or used as precursor of
GABA in GABAergic neurons.
The aim of this study was to explore the effects of
Ab(25-35) treatment on main transporters implicated in
sustaining synaptic release of amino acids, i.e. the gluta-
mine transporters SN1 and SAT1 and the vesicular
glutamate transporters VGLUT1 and VGLUT2, in two
different in vitro models: neuronal cell cultures and mixed
cell cultures of rat cerebral cortex.
Experimental procedures
Cell cultures
Neuronal cultures were prepared from embryos of Wistar
rats at day 18 of gestation (E18) using a modiﬁcation of an
earlier described method [12]. In brief, the neocortices of
embryos were dissociated by treatment with 0.25%
trypsin/calcium–magnesium-free buffer/EDTA for 10 min
at 37
 C. The suspension was settled for 2 min at 2,000 9 g
and then the cells were mixed in DMEM, triturated and
passed through a cell strainer. The cells were cultured in
DMEM supplemented with 2% B27 and 1% GlutaMAX I.
The cells were plated on poly-L-lysine (50 lg/ml) coated
glass coverslips at a density 0.5 9 10
6 cells/ml and the
cultures were maintained in a humidiﬁed atmosphere of 5%
CO2/95% air at 37
 C for 5 days in vitro before incubation
with peptide.
Primary mixed cell cultures were prepared from the
cerebral cortices of 1-day-old (P1) neonatal Wistar rats and
plated on poly-L-lysine-treated coverslips (see above). The
dissociated cortical cells were suspended in Neurobasal-A
medium containing 2% B27 and 1% GlutaMAX I and
maintained as described for E18 cells.
Rats were kept according to nationally and internation-
ally approved conditions. Culture media and reagents were
from Gibco, Invitrogen Corporation (Carlsbad, CA, USA).
Incubation with Ab peptide
Neuronal and mixed cell cultures were treated with Ab(25-
35) (Sigma-Aldrich, St.Louis, MO, USA) at ﬁnal concen-
trations of 3 and 10 lM, for 12 or 24 h. In this study the
B27-containing medium was removed from the cultures at
day 6. Cells were washed twice with DMEM or Neuro-
basal-A medium and then incubated in medium for 12 and
24 h in the absence or presence of Ab(25-35). Controls
received no peptide.
Antibodies
Antibody to SAT1 was raised in rabbit to a fusion protein
corresponding to the N-terminal amino acids 1-71 of SAT1
(aka GlnT, [13]; aka SA2, [14]), and afﬁnity puriﬁed and
characterized (T.T. Solbu & F.A. Chaudhry, to be published)
as described for SN1 [15]. A GST-fusion peptide was made
by cloning the ﬁrst 213 base pairs from SAT1 into a pGex3X
vector (Amersham Biosciences, GE Healthcare, Oslo,
Norway). Using primers 50- cccgggatccttatgatgcatttcaaa-30
and 50-gcggaattcggttgttcctggaat-30 (Eurogentech, Herstal,
Belgium), the 50 end of SAT1 was ampliﬁed by PCR and
ligated into pGex3X using BamH1 and EcoR1 (New England
Biolabs, Ipswich, MA, USA). GST-SAT1 was puriﬁed on
Gluthatione Sepharose 4B as prescribed by the manufacturer
(Amersham Biosciences; ‘‘GST Gene Fusion System Hand-
book’’). Antibodies to other transporters were prepared and
characterized as described (VGLUT1 and VGLUT2: [16];
SN1: [15]). Antibodies to marker proteins [glial ﬁbrillary
acidic protein (GFAP), anti-microtubule associated protein-
2A&B (MAP2)], raised in mice, were from Sigma-Aldrich.
Secondary antibodies were Alexa Fluor 488 goat anti-mouse
IgG and Alexa Fluor 555 goat anti-rabbit IgG from Molecular
Probes (Eugene, Oregon, USA).
Immunocytochemical staining
Following exposure to peptide, cells attached to 14-mm
glass coverslips were ﬁxed with formaldehyde (4%
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123paraformaldehyde, freshly depolymerized, in 0.1 M
sodium phosphate buffer pH 7.4) for 20 min at room
temperature followed by three washes in phosphate buf-
fered saline (10 mM phosphate buffer in 150 mM NaCl)
and then blocked with blocking buffer [10% (v/v) newborn
calf serum (NCS), 3% (w/v) bovine serum albumin (BSA),
0.5% (w/v) Triton X-100 in Tris buffered saline (TBS)
pH 7.4] for 1 h at room temperature. After blocking, sec-
tions were incubated with the primary antibodies (anti-
VGLUT1 1:3,000; anti-VGLUT2 1:3,000; anti-SAT1
2 mg/ml; anti-SN1 0.3 mg/ml; anti-MAP2 1:200; GFAP
1:500; dilutions optimized in pilot experiments) in primary
antibody solution [3% (v/v) NCS, 1% BSA, 0.5% Triton
X-100, 0.05% NaN3 in TBS pH 7.4] overnight at 4C, and
then the cells were washed and incubated with the sec-
ondary antibodies conjugated to Alexa Fluor 488 and
Alexa Fluor 555 for 1 h at room temperature. The cover-
slips were then washed three times in fresh antibody
solution. Cells on coverslips were sealed to microscopic
slides with Fluoromout G water based (Southern Biotech-
nology Associates, Birmingham, AL, USA).
Quantitative analysis of immunoreactivities
Dual immunoﬂuorescence for VGLUT1, VGLUT2,
SAT1, SN1, GFAP and MAP2 was examined and quan-
tiﬁed with a Zeiss Axioplan 2 microscope equipped with
an LSM 5 PASCAL confocal unit, LSM software and a
40x/1.3 oil PlanApo objective (Carl Zeiss, Heidelberg,
Germany). We used standard FICT-rhodamine ﬁlter set-
tings. Other settings were optimized initially, and held
constant throughout the study so that all sections were
digitized under the same conditions of illumination. Care
was taken to use similar times for orientation (with con-
ventional ﬂuorescence) and adjustments in all
preparations, in order to avoid differences in photoble-
aching. The cells were selected on the criterion that they
showed representative morphology (Fig. 1) and strong
immunoreactivity for MAP2 (neurons) or for SN1 (in the
case of astroglia). The cell body and the most proximal
parts of the processes were outlined for digitalization of
area and of ﬂuorescence intensity for two immunoreac-
tivities (MAP2 and a transporter). The analysis was
performed without notice of the treatment group; the lack
of difference in neuronal area between treatment groups
suggests that sampling bias did not interfere with the
results obtained. Fluorescence intensity is expressed in
arbitrary units, without subtraction of background. For
each glass coverslip, ﬁve ﬁelds were randomly sampled
and two cells quantiﬁed per ﬁeld, i.e. 10 cells, to obtain
an average value for each immunoreactivity and
experiment.
Data analysis
Data are expressed as mean ± standard error of the mean
(SEM) of four different experiments (four different sets of
cultures prepared at four different times) for P1 and E18
cultures. Advanced statistical analysis was performed
according to a linear mixed model regression analysis,
using the function lme of the nlme package [17] in the
statistical software R (http://www.r-project.org/). The
fundamental assumptions of the model are that the obser-
vations are normally distributed with a variance varying
only with protein type, and that they are uncorrelated when
they come from different experiments. Log (for P1 data) or
square root (for E18 data) transformations were performed
Fig. 1 Classiﬁcation of cell types. (a, c, e) MAP2 positive (green)
neuronal cells (arrowheads). (b) GFAP positive (red) astroglial cell
(arrow, same ﬁeld as a). (d, e) SN1 positive (red) astroglial cell
(arrow, same ﬁeld as c); SN1 (in contrast to GFAP) reveals the entire
extent of the astrocyte. (e) MAP2 and SN1 immunoreacivities
superimposed. (f) DIC image (same ﬁeld as c–e). Arrowheads and
arrows indicate the positions of the nuclei of sample neurons and
astrocytes, respectively. Note that all of the 10 cells situated on or
next to the astrocyte in (f) are identiﬁed as MAP2 positive neurons in
(c). Double immunoﬂuorescence observed by confocal microscopy in
mixed cell cultures from rat cortex at P1
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123as quantile–quantile plots showed these transformations to
give the best ﬁts to the Gaussian distribution.
Results
Cell types
Cell types were characterized in control cultures incubated
without Ab. In mixed neuronal–glial cultures (from cortex of
P1 rat pups), neurons and astroglia were clearly identiﬁed by
immunoreactivity for the markers MAP2 and GFAP,
respectively (Fig. 1a, b). Double labelling for MAP2 and
system N glutamine transporter SN1, localized in the mem-
branes of astroglia [15], again showed the two
immunoreactivities in separate cells (Fig. 1c–e), SN1 dis-
playing the full extension of protoplasmatic-like astrocytes
(i.e. beyond the parts pervaded by GFAP ﬁlaments, Fig. 1a,
b). The MAP2 expressing cells show the morphological
characteristics of neurons and usually grow in close apposi-
tion to astroglia (Fig. 1a–f). In neuronal cultures (from E18
rats), MAP2 positive neurons had similar morphology, but no
GFAP positive astroglial cells were found (not shown).
Double labelling for MAP2 and different transporter pro-
teins showed thevesicularglutamatetransportersVGLUT1 or
VGLUT2 to be in neurons. A slight signal for SN1 in neurons
was close to background levels. The system A glutamine
transporter SAT1 was mainly localized in neurons but slight
immunoreactivity was seen in some astroglial cells (Fig. 2a, b).
In the neurons, SAT1 staining was strong in central areas of
the perikaryon and pervaded the processes.
Survey of preparations double stained for MAP2 and
either VGLUT1 or VGLUT2 indicated that a large pro-
portion of the neurons were VGLUT immunoreactive.
Similarly, double staining for MAP2 and SAT1 suggested
that most of the neurons in the cultures contained SAT1.
Effects of Ab in mixed cell cultures
Cortical mixed cell cultures (P1) were exposed to Ab. After
day 5 in vitro cell cultures were incubated with 3 or 10 lM
of Ab(25-35) for 12 or 24 h and then processed for
immunohistochemistry and quantitative analyses. Neurons
with typical morphology and strong MAP2 staining were
seen also after exposure to Ab (Fig. 2c, d). The cells
appeared morphologically similar to those in control cul-
tures (Figs. 1, 2a, b). Transporter immunoreactivities were
quantitatively analysed (Fig. 3a, b) in neurons with typical
morphology and clear MAP2 immunoreactivity. In addi-
tion, SN1 was quantiﬁed in cells with typical astroglial
morphology according to SN1 immunoﬂuorescence. All
immunoreactivities showed a tendency for decline on
exposure to Ab(25-35), at 12 h as well as at 24 h, but this
attained statistical signiﬁcance only for SAT1. (The low
SN1 level in neurons is close to background and may not
be biologically signiﬁcant.) The size of the central areas of
the cells, over which the ﬂuorescence intensities were
recorded, was independent of peptide exposure in the
neurons and only slightly reduced (by about 16%) in the
glia (Fig. 3c, d). This indicates that, in the neurons recor-
ded, Ab treatment did not cause general impairment
resulting in a reduction of cell size.
To adjust for differences in the condition of the indi-
vidual cell, transporter immunoreactivity was expressed
relative to the simultaneously recorded MAP2 immunore-
activity of the same cell (Fig. 3e, f). In this analysis, the
effect of Ab on SAT1 stood out even more clearly,
showing the largest percentage changes, whereas there
were no statistically signiﬁcant effects of Ab on VGLUT1,
VGLUT2 or SN1 in neurons, neither on SN1 in astroglia.
After both 12 and 24 h incubation, SAT1 was reduced to
about two thirds of the control level by 3 lMo fA b, and
about one half by 10 lMo fA b. As statistical tests showed
similar effects at 12 and 24 h, the data were reanalysed
statistically with a simpliﬁed linear mixed model assuming
the same ﬁxed effect at 12 and 24 h. This analysis gave
higher statistical signiﬁcance for the effect on SAT1
(P = 0.0009 at 3 lM, P = 0.0000 at 10 lM) than did the
full model reported in Fig. 3. It conﬁrmed the lack of effect
on the other transporters (P[0.2), and the lack of effect
on perikaryal size (P[0.1), except for the size of SN1
positive glia (P\0.03 for 3 lM, P\0.01 for 10 lM).
Lack of effect of Ab in neuronal cell cultures
Cultured cortical neurons (E18) were exposed to Ab(25-
35) in the same way as for P1 mixed cell cultures. MAP2
positive neurons had a similar appearance as in P1 cultures,
in controls as well as after exposure to Ab (Fig. 4a–d).
Quantiﬁcation of the ﬂuorescence intensities (Fig. 5)
indicated slight effects of Ab on SAT1 and SN1 (Fig. 5a,
b), but not on the other transporters, or on cell area
(Fig. 5c, d). However, when the ﬂuorescence intensity for
transporter was normalized to that for MAP2 in the same
cell, there were no signiﬁcant effects of Ab, except on SN1
(which in neurons is very low and of questionable bio-
logical signiﬁcance). Statistical tests suggested no
difference between 12 and 24 h or between 3 and 10 lM.
When statistically analysed according to a simpliﬁed linear
mixed model, assuming the same ﬁxed effect for the dif-
ferent incubation times and concentrations of Ab, there
were no signiﬁcant effects of Ab on any of the transporter
immunoreactivities (P C 0.07).
Finally, to test more directly whether the results differed
between the two types of culture used, the MAP2
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into one linear mixed model for regression analysis. The
ﬁxed effect was now deﬁned as the expected difference in
effect of Ab exposure between P1 and E18 cultures.
Assuming the same ﬁxed effect at 12 and 24 h, the effect
on SAT1 was signiﬁcantly different between neurons in P1
and E18 cultures (P = 0.016 for 3 lM, P = 0.010 for
10 lMo fA b) but those on the other transporters were not
(P[0.3). Assuming similar effect at the two concentra-
tions of Ab, the signiﬁcance level was even higher (SAT1
P = 0.004; other transporters P[0.2).
Discussion
The main ﬁnding of the present study is that Ab causes a
reduction in neuronal SAT1, a transporter thought to be
essential for neuronal uptake of glutamine [9, 13, 14]t o
support neuronal function including the formation of neu-
rotransmitter in glutamatergic as well as GABAergic
neurons. The transmitter of the neurons loosing SAT1 was
not directly identiﬁed, but as double labelling for MAP2
with VGLUTs and MAP2 with SAT1 both showed major
proportions of double labelled cells, they are likely to
comprise glutamatergic neurons.
The concentrations of Ab were selected on the basis of
literature data to be effective but with low to moderate
toxicity levels [12]. To further minimize confounding
inﬂuence of indiscriminate toxic damage, the immunore-
activities were measured in individual cells that showed
near normal morphology and near normal immunoreac-
tivity for the neuronal marker MAP2. Therefore, unlike in
biochemical studies of whole cultures, cells dying or dead
Fig. 2 SAT1 (red) colocalized (yellow-orange) with MAP2 (green)
in neurons in P1 cortical mixed cell cultures. Images show sample
cells, insets display framed areas separately for SAT1 immunoreac-
tivity. Cultures were exposed to control medium for 12 h (a)o r2 4h
(b), or to 10 lMo fA b(25-35) for 12 h (c)o r2 4h( d). SAT1 is
expressed in the soma and processes of neurons, as revealed by
double labelling with antibodies to the somatodendritic neuronal
marker MAP2 shown superimposed on SAT1. Foci of strong
perikaryal immunoreactivity suggest intracellular stores of SAT1.
(Slight SAT1 immunoreactivity occurs also in glia-like perikarya (b,
centre right, arrow), immunonegative for MAP2.) The immunoreac-
tive cells were morphologically similar in the different conditions (a–
d). Scale bar = 20 lm
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123Fig. 3 Ab induced a reduction of SAT1 immunoreactivity in neurons
in P1 mixed cortical cell cultures. Transporter immunoreactivities
(arbitrary units of ﬂuorescence intensity, FL) and areas (lm
2) were
recorded in individual cells in cultures incubated with 0, 3 or 10 lM
Ab(25-35) for 12 h (a, c, e)o r2 4h( b, d, f). Areas (c, d) comprising
the perikaryon and proximal neurites were outlinded for recording of
an average ﬂuorescence intensity in each cell. To cancel out random
differences between cells, transporter immunoreactivity was also
expressed relative to MAP2 immunoreactivity in the same cell (e, f).
All values are for neurons, except for SN1, which was recorded also
in astroglial cells (area and relative immunoreactivity for SN1 in glia
were 40 times the displayed numbers). Background was not
subtracted; the low values for SN1 in neurons are close to non-
immunoreactive background. Columns show mean + SEM of mea-
surements from four independent experiments (n = 4), in each
experiment 10 cells were averaged. Asterisks indicate a statistically
signiﬁcant difference compared with control (*P B 0.05, **P
B 0.01, ***P B 0.001) in a linear mixed model regression analysis
(statistical software R). Only SAT1 showed a robust effect of Ab
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Further, random variation in the condition of cells was
corrected for by expressing the transporter immunoreac-
tivities relative to that of MAP2, measured in the same cell
by double immunoﬂuorescence. Ab peptides have been
found to induce proteolysis of MAP2 in cultured mouse
cortical neurons [18], but in the cells sampled in the present
study such proteolysis must have been minor, as the rela-
tion between the values for the different transporters and
conditions were similar whether expressed as ﬂuorescence
units or relative to MAP2 ﬂuorescence units.
The effect of Ab on neuronal SAT1 was observed in
cultures containing neurons in close apposition to astroglial
cells, but not in neuronal cultures without glia. This sug-
gests that Ab does not produce the effect by acting directly
on the neurons, but via the glial cells, an idea gaining some
support from the observed reduction in astroglial cell size.
However, as the astrocytes had only slightly reduced size
and normal levels of their marker protein SN1, the changes
in neuronal SAT1 cannot be ascribed simply to toxic
damage in the glia.
The ﬁndings are consistent with previous reports that the
presence of astrocytes enhances Ab induced neurotoxicity
in hippocampal cell cultures [19] and that the presence of
reactive astrocytes is a characteristic feature of the lesions
in AD brain [20]. Notwithstanding, the effect on neuronal
SAT1 cannot be ascribed simply to an indiscriminate toxic
inﬂuence on the neurons from the Ab exposed glia, because
there was no similar effect on VGLUTs, and because the
effect was observed in neurons with apparently normal
morphology and normal expression of the neuronal marker
MAP2. Could the reduced level of neuronal SAT1 con-
tribute to the impaired resistance of neurons to Ab when
cultured in the presence of glia? While this does not appear
likely, the observed 50% reduction in glutamine transporter
level might possibly be critical in certain conditions.
Fig. 4 SAT1 (red) colocalized (yellow-orange) with MAP2 (green)
in neurons in E18 cortical neuronal cell cultures. Sample neurons are
shown. The immunoreactive cells were morphologically similar to
those in P1 cultures (Fig. 2). No glia-like cells were present. Cells
were incubated in the absence (a, b) or presence of 10 lMA b(25-35)
(c, d) for 12 h (a, c)o r2 4h( b, d). Labelling was strong in the
perinuclear region and processes of neurons. Scale bar = 20 lm
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123The mechanism by which astroglial cells cause changes
in neuronal expression of SAT1 must be determined by
future research. As free radicals and oxidative stress play
important parts in AD [21], it is interesting that crotonal-
dehyde accumulates in reactive astrocytes in AD brain
[22]. Astrocytes mediate Ab induced neuronal death
through oxidative stress [23]. One possible mediator of the
observed glia-neuron inﬂuence is BDNF signalling, which
is impaired in cortical neuron cultures exposed to Ab [24,
25], although Ab may affect this signalling cascade without
the participation of glia [24]. An attractive possibility is
offered by the observation that Ab(25-35) causes astrocytes
to produce nerve growth factor (NGF), thereby inducing
tau hyperphosphorylation and reduced survival in hippo-
campal neurons [26]. As the effect is exacerbated by NO,
this mechanism may offer a link with the effects of free
Fig. 5 Lack of effect of Ab on SAT1 immunoreactivity in E18 cortical neuronal cells (cultured without glia). Data were obtained and presented
as in Fig. 3
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123radicals in AD pathology. It ﬁts with the recent observation
that reduction of endogenous tau protects against Ab tox-
icity in a mouse model of AD [27].
The mechanism of vulnerability of neurons in AD
appears to involve excitotoxicity [4]. The increase in glial
glutamate transporters induced by Ab [28] may represent a
measure to limit excitotoxic damage. Similarly, the
reduced neuronal levels of SAT1 observed here after
exposure to Ab may limit the production of glutamate, but
also of GABA, for synaptic release. It might represent an
adaptation to curb excitotoxicity in AD, but might con-
comitantly impair synaptic function.
Acknowledgements This work was supported by the Thailand
Research Fund through the Royal Golden Jubilee Ph.D. Program
(Grant No. PHD/0230/2545), and by the Research Council of
Norway.
References
1. Mattson MP (2004) Pathways towards and away from Alzhei-
mer’s disease. Nature 430:631–639
2. Goedert M, Spillantini MG (2006) A century of Alzheimer’s
disease. Science 314:777–781
3. Kasa P, Papp H, Kasa Jr P et al (2004) Effects of amyloid-beta on
cholinergic and acetylcholinesterase-positive cells in cultured
basal forebrain neurons of embryonic rat brain. Brain Res
998:73–82
4. Mattson MP, Cheng B, Davis D et al (1992) b-Amyloid peptides
destabilize calcium homeostasis and render human cortical neu-
rons vulnerable to excitotoxicity. J Neurosci 12:376–389
5. Varadarajan S, Kanski J, Aksenova M et al (2001). Different
mechanisms of oxidative stress and neurotoxicity for Alzheimer’s
Ab(1–42) and Ab(25-35). J Am Chem Soc 123:5625–5631
6. Fonnum F (1984) Glutamate: a neurotransmitter in mammalian
brain. J Neurochem 42:1–11
7. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1–105
8. Armano S, Coco S, Bacci A et al (2002) Localization and
functional relevance of system A neutral amino acid transporters
in cultured hippocampal neurons. J Biol Chem 277:10467–10473
9. Chaudhry FA, Reimer RJ, Edwards RH (2002) The glutamine
commute: take the N line and transfer to the A. J Cell Biol
157:349–355
10. Fremeau RT Jr, Voglmaier S, Seal RP et al (2004) VGLUTs
deﬁne subsets of excitatory neurons and suggest novel roles for
glutamate. Trends Neurosci 27:98–103
11. Shigeri Y, Seal RP, Shimamoto K (2004) Molecular pharma-
cology of glutamate transporters, EAATs and VGLUTs. Brain
Res Rev 45:250–265
12. Tong L, Thornton PL, Balazs R et al (2001) b-amyloid-(1-42)
impairs activity-dependent cAMP-response element-binding
protein signaling in neurons at concentrations in which cell sur-
vival is not compromised. J Biol Chem 276: 17301–17306
13. Varoqui H, Zhu H, Yao D et al (2000) Cloning and functional
identiﬁcation of a neuronal glutamine transporter. J Biol Chem
275:4049–4054
14. Chaudhry FA, Schmitz D, Reimer RJ et al (2002). Glutamine
uptake by neurons: interaction of protons with system A trans-
porters. J Neurosci 22:62–72
15. Boulland JL, Osen KK, Levy LM et al (2002) Cell-speciﬁc
expression of the glutamine transporter SN1 suggests differences
in dependence on the glutamine cycle. Eur J Neurosci 15:
1615–1631
16. Fremeau RT, Troyer MD, Pahner I et al (2001) The expression of
vesicular glutamate transporters deﬁnes two classes of excitatory
synapse. Neuron 31:247–260
17. Pinheiro JC, Bates DM (2002) Mixed effects models in S and S-
PLUS. Springer, New York
18. Fifre A, Sponne I, Koziel V et al (2006) Microtubule-associated
protein MAP1A, MAP1B, and MAP2 proteolysis during soluble
amyloid b-peptide-induced neuronal apoptosis. Synergistic
involvement of calpain and caspase-3. J Biol Chem 281:229–240
19. Domenici MR, Paradisi S, Sacchetti B et al (2002) The presence
of astrocytes enhances beta amyloid-induced neurotoxicity in
hippocampal cell cultures. J Physiol Paris 96:313–316
20. Meda L, Baron P, Scarlato G (2001) Glial activation in Alzhei-
mer’s disease: the role of Ab and its associated proteins.
Neurobiol Aging 22:885–893
21. Pratico D, Delanty N (2000) Oxidative injury in diseases of the
central nervous system: focus on Alzheimer’s disease. Am J Med
109:577–585
22. Kawaguchi-Niida M, Shibata N, Morikawa S et al (2006) Cro-
tonaldehyde accumulates in glial cells of Alzheimer’s disease
brain. Acta Neuropathol 111:422–429
23. Abramov AY, Canevari L, Duchen MR (2004) b-Amyloid pep-
tides induce mitochondrial dysfunction and oxidative stress in
astrocytes and death of neurons through activation of NADPH
oxidase. J Neurosci 24:565–575
24. Tong L, Balazs R, Thornton PL et al (2004) b-Amyloid peptide
at sublethal concentrations downregulates brain-derived neuro-
trophic factor functions in cultured cortical neurons. J Neurosci
24:6799–6809.
25. Wang DC, Chen SS, Lee YC et al (2006) Amyloid-b at sublethal
level impairs BDNF-induced arc expression in cortical neurons.
Neurosci Lett 398:78–82
26. Saez ET, Pehar M, Vargas MR et al (2006) Production of nerve
growth factor by b-amyloid-stimulated astrocytes induces
p75NTR-dependent tau hyperphosphorylation in cultured hippo-
campal neurons. J Neurosci Res 84:1098–1106
27. Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing
endogenous tau ameliorates amyloid b-induced deﬁcits in an
Alzheimer’s disease mouse model. Science 316:750–754
28. Baba A, Mitsumori K, Yamada MK et al (2003) b-Amyloid
prevents excitotoxicity via recruitment of glial glutamate trans-
porters. Naunyn Schmiedebergs Arch Pharmacol 368:234–238
256 Neurochem Res (2008) 33:248–256
123